MAO-inhibitors in Parkinson's Disease
- Biology, MedicineExperimental neurobiology
In general, the clinical use of MAO-I nowadays is underestimated and there should be more efforts to evaluate their clinical potency as antidepressants and antidementive drugs in addition to the final proof of their disease-modifying potential.
Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells.
- Biology, ChemistryJournal of neural transmission. Supplementum
Monoamine oxidases A and B (MAO A and MAO B) are the major enzymes that catalyze the oxidative deamination of monoamine neurotaransmitters such as dopamine (DA), noradrenaline, and serotonin in the…
One pot synthesis of propargylamines by three component amine-aldehyde-acetylene (A3) coupling catalyzed by neutral Ag(I) and Au(I) and cationic Pd(II) and Ni(II) complexes of a pincer N-heterocyclic carbene
- ChemistryMolecular Catalysis
Revisiting the Role of Astrocytic MAOB in Parkinson’s Disease
- Biology, ChemistryInternational journal of molecular sciences
The role of MAOB is redefined for the aberrant suppression and deterioration of dopaminergic neurons through excessive GABA and H2O2 synthesis of reactive astrocytes in PD.
Pharmacological management of Parkinson’s disease in older people
- Medicine, Psychology
An evidence‐based review of Parkinson’s disease treatments and guidance to improve clinical management and outcomes in older people is presented.
Safety and Tolerability of Pharmacotherapies for Parkinson’s Disease in Geriatric Patients
- Medicine, PsychologyDrugs & Aging
Geriatric patients with Parkinson’s disease experience a specific profile of comorbidities and an international register concerning issues of safer drug application and monitoring could help to implement a better treatment.
Practical synthesis of silyl-protected and functionalized propargylamines using nanostructured Ag/TiO2 and Pt/TiO2 as active recyclable catalysts
- ChemistryChemical Papers
Herein we report the use of Ag/TiO2 and Pt/TiO2 nanocatalysts to promote the synthesis of a series of silyl-protected and functionalized propargylamine derivatives through alkyne–amine–aldehyde (A3)…
Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson's disease.
- Biology, MedicineMedical hypotheses
90 years of monoamine oxidase: some progress and some confusion
- BiologyJournal of Neural Transmission
This account concentrates key advances that explain why the monoamine oxidases remain of pharmacological and biochemical interest and on some areas of continuing uncertainty.
SHOWING 1-10 OF 36 REFERENCES
Half-life time for striatal MAO-B recovery is 9,23 days
- Youdim and Tipton
necessary to avoid increase of dopamine) reached only 31 hours after enzyme blockade with tranylcypromine. For PEA this value is 70 hours
Symptomatic effect of selegiline in de novo parkinsonian patients
- Medicine, PsychologyMovement disorders : official journal of the Movement Disorder Society
Selegiline was significantly superior to placebo on the various motor rating scores, and depressive scores were significantly improved at the end of 3 months, Therefore, selegilines could be the therapy of choice for the treatment of de novo parkinsonian patients.
Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease.
- Biology, ChemistryParkinsonism & related disorders
Slow recovery of human brain MAO B after L‐Deprenyl (Selegeline) withdrawal
The slow turnover of brain MAO B suggests that the current clinical dose of L‐deprenyl may be excessive and that the clinical efficacy of reduced dosing should be evaluated, and the first measurement of the synthesis rate of a specific protein in the living human brain is measured.
- J Neurochem
Die Parkinson-Krankheit, auch Morbus Parkinson, ist mit einer Pravalenz von 1:1000 eine der haufigsten neurologischen Erkrankungen, wobei die Inzidenz mit dem Alter zunimmt. So leiden von den…
Selegiline as the primary treatment of Parkinson's disease — a long‐term double‐blind study
- Medicine, PsychologyActa neurologica Scandinavica
Selegiline therapy offers beneficial long‐term effects in the treatment of PD and induced a significant slowing in the need to increase the daily levodopa dose in order to compensate for the progression of the disease.
The effect of deprenyl and levodopa on the progression of Parkinson's disease
- MedicineAnnals of neurology
It is demonstrated that deprenyl attenuates deterioration in UPDRS score in patients with early Parkinson's disease and this findings are consistent with the hypothesis thatdeprenyl has a neuroprotective effect.
EVIDENCE FOR DOPAMINE DEAMINATION BY BOTH TYPE A AND TYPE B MONOAMINE OXIDASE IN RAT BRAIN in vivo AND FOR THE DEGREE OF INHIBITION OF ENZYME NECESSARY FOR INCREASED FUNCTIONAL ACTIVITY OF DOPAMINE AND 5‐HYDROXYTRYPTAMINE
- Biology, ChemistryBritish journal of pharmacology
1 Tranylcypromine (20 mg/kg) administration to rats totally inhibited brain monoamine oxidase (MAO) oxidation of 5‐hydroxytryptamine (5‐HT), phenylethylamine and dopamine as measured in vitro. When…